Home › Plexxikon and Merck to Collaborate on Combination Study Evaluating Investigational Immuno-oncology Regimen
 

Keywords :   


Plexxikon and Merck to Collaborate on Combination Study Evaluating Investigational Immuno-oncology Regimen

2015-05-07 14:30:00| Merck.com - Product News

Dateline City: BERKELEY, Calif., and KENILWORTH, N.J. Study will Evaluate Mercks Anti-PD-1 Therapy, KEYTRUDA (pembrolizumab), in Combination with Plexxikons PLX3397 BERKELEY, Calif., and KENILWORTH, N.J. May 7, 2015 Plexxikon Inc., a member of Daiichi Sankyo Group, and Merck (NYSE:MRK), known as MSD outside the US and Canada, through a subsidiary, today announced a collaborative clinical trial that will evaluate the combination of PLX3397, Plexxikons investigational CSF-1R inhibitor, and KEYTRUDA (pembrolizumab), Mercks anti-PD-1 therapy, which provides the potential for a double blockade of cancer-induced immune suppression. Language: English read more

Tags: study combination evaluating collaborate

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
16.05CFTC charges Agridime and its co-founders with a fraudulent cattle scheme
16.05Baleage: Advantageous for first cutting hay
16.05Hydrosome Labs Technology Poised to Usher in New Era of Precision Fermentation
16.05Tools for environmental challenge
16.05Hubbl integrates global streaming apps with Amdocs
16.05Croda Beauty Launches New Ceramide Range
16.05Doves New Bond Strength Range Contains Proprietary Bio-Protein Care and Peptides
16.05Mount Sinai Awarded $6.6 Million from National Institutes of Health to Investigate Treatment ...
More »